Amping up With PemJAK

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

Trial Details

NCT ID
NCT07283822
Phase
PHASE2
Sponsor
Seda S. Tolu
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Ruxolitinib
  • Pembrolizumab
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • (1) Histologically confirmed relapsed/refractory HL, PMBCL, GZL, and TCL including the below subtypes:
  • Arm 1: PTCL
  • Nodal PTCL Peripheral T-cell Lymphoma- Not Otherwise Specified (PTCL-NOS)
  • Anaplastic Large Cell Lymphoma (ALCL) T-follicular Helper Lymphomas (TFH) and its subtypes including angioimmunoblastic T-cell Lymphoma (AITL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →